James M. Frates - 03 Jan 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Reporting relationship: Director
Issuer ticker: SAGE
Reported as of: 03 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2025, 16:02:45 UTC
Prior SEC filing: 16 Sep 2024
Next SEC filing: 10 Mar 2025
Source filing: View source filing
Reporting owner signature: Brandon Marsh, as Attorney-in-Fact for James M Frates

Key filing fact

James M. Frates filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 06 Jan 2025.

Key facts

This page summarizes James M. Frates's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2025, 16:02.

Change

Previous filing in this sequence was filed on 16 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SAGE transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $0
Shares: +19,154
Change %
Price: $0.000000
Shares after: 19,154
Date: 03 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,154
Exercise price: $6.14
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2025 on the issuer's board or its committees, as permitted under the issuer's non-employee director compensation program. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. The option will vest in full on December 31, 2025, subject to the reporting person's continued service through such date.